SG169983A1 - Aspartic protease inhibitors - Google Patents

Aspartic protease inhibitors

Info

Publication number
SG169983A1
SG169983A1 SG201101062-6A SG2011010626A SG169983A1 SG 169983 A1 SG169983 A1 SG 169983A1 SG 2011010626 A SG2011010626 A SG 2011010626A SG 169983 A1 SG169983 A1 SG 169983A1
Authority
SG
Singapore
Prior art keywords
aspartic protease
protease inhibitors
present
directed
aspartic
Prior art date
Application number
SG201101062-6A
Other languages
English (en)
Inventor
John J Baldwin
David A Claremon
Colin Tice
Salvacion Cacatian
Lawrence W Dillard
Alexey V Ishchenko
Jing Yuan
Zhenrong Xu
Gerard Mcgeehan
Robert D Simpson
Suresh B Singh
Wei Zhao
Patrick T Flaherty
Original Assignee
Vitae Pharmaceuticals Inc Us
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitae Pharmaceuticals Inc Us filed Critical Vitae Pharmaceuticals Inc Us
Publication of SG169983A1 publication Critical patent/SG169983A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
SG201101062-6A 2005-11-14 2006-11-13 Aspartic protease inhibitors SG169983A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73656405P 2005-11-14 2005-11-14
US84533106P 2006-09-18 2006-09-18
US84529106P 2006-09-18 2006-09-18

Publications (1)

Publication Number Publication Date
SG169983A1 true SG169983A1 (en) 2011-04-29

Family

ID=37812974

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201101062-6A SG169983A1 (en) 2005-11-14 2006-11-13 Aspartic protease inhibitors

Country Status (16)

Country Link
US (1) US8487108B2 (fr)
EP (1) EP1966139B1 (fr)
JP (1) JP2009515893A (fr)
KR (1) KR101379663B1 (fr)
AR (1) AR057890A1 (fr)
AT (1) ATE538092T1 (fr)
AU (1) AU2006325322B2 (fr)
BR (1) BRPI0618585A2 (fr)
CA (1) CA2628952C (fr)
HK (1) HK1121459A1 (fr)
NO (1) NO20082108L (fr)
NZ (1) NZ568042A (fr)
PE (2) PE20070804A1 (fr)
SG (1) SG169983A1 (fr)
TW (1) TWI411607B (fr)
WO (1) WO2007070201A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2440993C2 (ru) 2004-10-07 2012-01-27 Вайти Фармасьютикл, Инк. Диаминоалкановые ингибиторы аспарагиновой протеазы
US7858624B2 (en) * 2006-04-05 2010-12-28 Vitae Pharmaceuticals, Inc. Piperidine and morpholine renin inhibitors
US20090275581A1 (en) * 2006-04-05 2009-11-05 Baldwin John J Renin inhibitors
US20090264428A1 (en) * 2006-04-05 2009-10-22 Baldwin John J Renin Inhibitors
US7872028B2 (en) 2006-04-05 2011-01-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
WO2008036216A1 (fr) * 2006-09-18 2008-03-27 Vitae Pharmaceuticals, Inc. Derives de piperidine utilises en tant qu'inhibiteurs de renine
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
WO2009038715A1 (fr) * 2007-09-17 2009-03-26 Vitae Pharmaceuticals, Inc. Procédé de préparation d'inhibiteurs de la rénine
US8242290B2 (en) 2007-09-17 2012-08-14 Vitae Pharmaceuticals, Inc. Process for the preparation of renin inhibitors
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US20100010228A1 (en) * 2008-06-26 2010-01-14 Vitae Pharmaceuticals, Inc. Process for the asymmetric reduction of 3-benzoylpiperidines
MX2010014557A (es) * 2008-06-26 2011-02-15 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil)((r)-1-((s)-2-(metilamino)-3-((r)-te trahidro-2h-piran-3-il)propilcarbamoil)piperidin-3-il)metoxi)etil carbamato de metilo.
RU2478636C2 (ru) 2008-08-05 2013-04-10 Дайити Санкио Компани, Лимитед ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДИН-2-ОНА, ОБЛАДАЮЩИЕ mTOR ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ
WO2010111634A2 (fr) * 2009-03-26 2010-09-30 Takeda Pharmaceutical Company Limited Inhibiteurs de la rénine
US20110021570A1 (en) 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2012081585A1 (fr) * 2010-12-15 2012-06-21 国立大学法人北海道大学 Procédé de fabrication de composé alcool optiquement actif
WO2012081582A1 (fr) * 2010-12-15 2012-06-21 国立大学法人北海道大学 Procédé de fabrication de composé alcool de manière diastéréosélective, et composé ruthénium
MX2015002036A (es) 2012-08-16 2016-01-22 Janssen Pharmaceutica Nv Pirazoles sustituidos como bloqueadores del canal de calcio tipo n.
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
WO2023217989A1 (fr) 2022-05-12 2023-11-16 Syngenta Crop Protection Ag Composés alcoxy hétéroaryl-carboxamide ou thioamide
WO2024033374A1 (fr) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Nouveaux composés arylcarboxamide ou arylthioamide
WO2024126650A1 (fr) 2022-12-15 2024-06-20 Syngenta Crop Protection Ag Nouveaux composés bicycliques-carboxamide utiles en tant que pesticides

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3071618A (en) * 1956-02-02 1963-01-01 Pfizer & Co C Diquaternary ammonium salts of n, n, n', n'-tetra substituted alkylene diamines
GB1351761A (en) 1971-02-04 1974-05-01 Wilkinson Sword Ltd Substituted p-menthane carboxamides and compositions containing them
US4136163A (en) * 1971-02-04 1979-01-23 Wilkinson Sword Limited P-menthane carboxamides having a physiological cooling effect
JPS5115098A (ja) 1974-07-26 1976-02-06 Asahi Chemical Ind Akurirukeiseniseihinno shorihoho
US4594343A (en) 1984-10-19 1986-06-10 Shanklin Jr James R 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
GB8810067D0 (en) * 1988-04-28 1988-06-02 Ucb Sa Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides
US4908372A (en) * 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
DE4018070A1 (de) * 1990-06-06 1991-12-12 Bayer Ag Morpholinoharnstoff-derivate
HUT64320A (en) * 1990-12-14 1993-12-28 Merrell Dow Pharma Process for production antiallergic imidazole derivatives and pharmaceutical preparations containing these compounds
PT626968E (pt) * 1992-02-13 2002-03-28 Merrell Pharma Inc Derivados de piperidinilo tiaciclicos
ATE187160T1 (de) 1994-07-29 1999-12-15 Abbott Lab Verfahren zur herstellung eines substituierten 2,5-diamino-3-hydroxy hexanes
US5767144A (en) * 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US6162927A (en) * 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US6946481B1 (en) * 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
CA2291157A1 (fr) 1997-05-29 1998-12-03 Eli Lilly And Company Procede utiles pour la preparation de composes heterocycliques
WO1999054321A1 (fr) 1998-04-21 1999-10-28 Aventis Pharma Limited Diamines substituees et leur utilisation en tant qu'inhibiteurs d'adhesion cellulaire
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
GB9826540D0 (en) * 1998-12-02 1999-01-27 Darwin Discovery Ltd Process
AU2492500A (en) 1999-01-06 2000-07-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aspartic protease inhibitors, compositions, and associated therapeutic methods
JP2000302757A (ja) 1999-04-16 2000-10-31 Shiseido Co Ltd Ｎ−置換ピペリジン誘導体
SK13632002A3 (sk) * 2000-03-21 2003-02-04 Smithkline Beecham Corporation C1-6-alkyl-4-amino-azepán-3-ónové zlúčeniny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom, ich použitie a medziprodukty
US6900329B2 (en) * 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
JP4278511B2 (ja) 2001-07-11 2009-06-17 イーラン ファーマスーティカルズ、インコーポレイテッド Ｎ−（３−アミノ−２−ヒドロキシ−プロピル）置換アルキルアミド化合物
AU2002359376B2 (en) * 2001-11-08 2008-01-10 Elan Pharmaceuticals, Inc. N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
KR100987815B1 (ko) 2002-04-26 2010-10-18 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 프로테아제 억제제 화합물의 포스포네이트유사체의 세포 축적
WO2004002483A1 (fr) * 2002-06-27 2004-01-08 Actelion Pharmaceuticals Ltd 3- et 4- aminomethylpiperidines substituees utilisees comme beta-secretase dans le traitement de la maladie d'alzheimer
US7557137B2 (en) 2002-08-05 2009-07-07 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
BR0314180A (pt) 2002-09-10 2005-08-09 Pharmacia & Upjohn Co Llc Aminoéteres substituìdos para o tratamento da doença de alzheimer
NZ546887A (en) 2003-11-03 2009-04-30 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US20070093492A1 (en) * 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
WO2006023844A2 (fr) 2004-08-20 2006-03-02 Entremed, Inc. Compositions et procedes comportant des antagonistes de recepteur active par la proteinase
RU2440993C2 (ru) * 2004-10-07 2012-01-27 Вайти Фармасьютикл, Инк. Диаминоалкановые ингибиторы аспарагиновой протеазы
US7585886B2 (en) 2005-05-19 2009-09-08 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
US7858624B2 (en) * 2006-04-05 2010-12-28 Vitae Pharmaceuticals, Inc. Piperidine and morpholine renin inhibitors
US7872028B2 (en) * 2006-04-05 2011-01-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
CL2007002689A1 (es) * 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
WO2008036216A1 (fr) 2006-09-18 2008-03-27 Vitae Pharmaceuticals, Inc. Derives de piperidine utilises en tant qu'inhibiteurs de renine
EP2170815A2 (fr) * 2007-06-20 2010-04-07 Vitae Pharmaceuticals, Inc. Inhibiteurs de la renine
WO2009096996A1 (fr) 2007-06-20 2009-08-06 Smithkline Beecham Corporation Inhibiteurs de la rénine
US7773441B2 (en) * 2008-06-18 2010-08-10 Micron Technology, Inc. Memory malfunction prediction system and method
US20110160300A1 (en) 2008-06-20 2011-06-30 Marlys Hammond Renin Inhibitors and Methods of Use Thereof
MX2010014557A (es) 2008-06-26 2011-02-15 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil)((r)-1-((s)-2-(metilamino)-3-((r)-te trahidro-2h-piran-3-il)propilcarbamoil)piperidin-3-il)metoxi)etil carbamato de metilo.
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo

Also Published As

Publication number Publication date
CA2628952A1 (fr) 2007-06-21
CA2628952C (fr) 2014-04-01
AU2006325322B2 (en) 2011-08-04
TWI411607B (zh) 2013-10-11
US8487108B2 (en) 2013-07-16
JP2009515893A (ja) 2009-04-16
KR101379663B1 (ko) 2014-04-14
EP1966139B1 (fr) 2011-12-21
PE20070804A1 (es) 2007-09-06
US20100048636A1 (en) 2010-02-25
AR057890A1 (es) 2007-12-26
AU2006325322A1 (en) 2007-06-21
WO2007070201A1 (fr) 2007-06-21
HK1121459A1 (en) 2009-04-24
KR20080069685A (ko) 2008-07-28
EP1966139A1 (fr) 2008-09-10
TW200800893A (en) 2008-01-01
NZ568042A (en) 2010-12-24
ATE538092T1 (de) 2012-01-15
BRPI0618585A2 (pt) 2011-09-27
PE20120229A1 (es) 2012-04-04
NO20082108L (no) 2008-08-06

Similar Documents

Publication Publication Date Title
SG169983A1 (en) Aspartic protease inhibitors
MX2009002740A (es) Inhibidores de renina.
ATE520690T1 (de) Piperidinderivate als renin-inhibitoren
GEP20094679B (en) Dipeptidyl peptidase inhibitors
TW200740803A (en) Heterocyclic derivatives as modulators of ion channels
TW200718424A (en) Novel compounds of amino sulfonyl derivatives
MX2009003763A (es) Inhibidores de metaloproteasa derivados de heterociclicos.
MX2013006598A (es) Inhibidores de la amida hidrolasa de acidos grasos (faah).
EP1248612A4 (fr) Nouveaux composes et compositions utilises comme inhibiteurs de protease
WO2003002531A3 (fr) Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase
TW200745089A (en) Novel compounds that are ERK inhibitors
SG162790A1 (en) Aspartyl protease inhibitors
TW200716644A (en) Aspartyl protease inhibitors
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
WO2003002530A3 (fr) Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase
WO2004047735A3 (fr) Therapies et prophylaxie anti-virus a large spectre
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
WO2007146284A3 (fr) Thiénopyrimidines utiles en tant que modulateurs de canaux ioniques
TW200628158A (en) Promoting neochondrogenesis using kinase inhibitors
PL1789398T3 (pl) Pochodne 2-amino-chinazoliny użyteczne jako inhibitory ß-sekretazy (BACE)
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
ZA200710332B (en) Bicyclic derivatives as modulators of ion channels
TW200510311A (en) CCr8 inhibitors
WO2006023866A3 (fr) Acides thiazolo-naphthyliques
TW200718695A (en) Novel piperidine carboxylic acid amide derivatives